130 related articles for article (PubMed ID: 33046405)
1. Esophageal Dysphagia and Recurrent Aspiration From Treatment-Induced Neuropathy of Diabetes in an Adult Patient With Type 1 Diabetes.
Oleynick C; Prosperi-Porta G; Wilson BJ
Can J Diabetes; 2021 Mar; 45(2):105-107.e1. PubMed ID: 33046405
[No Abstract] [Full Text] [Related]
2. Decrease in clinical hypoglycemia in young children with type 1 diabetes treated with free-mixed aspart and detemir insulin: an open labeled randomized trial.
Petit-Bibal C; Rothenbuhler A; Lucchini P; Aboumrad B; Castell AL; Le Fur S; Bougnères P
Pediatr Diabetes; 2015 Aug; 16(5):345-53. PubMed ID: 24888575
[TBL] [Abstract][Full Text] [Related]
3. Treatment-induced neuropathy of diabetes related to abrupt glycemic control.
Stainforth-Dubois M; McDonald EG
CMAJ; 2021 Jul; 193(28):E1085-E1088. PubMed ID: 34281965
[No Abstract] [Full Text] [Related]
4. Twice- rather than once-daily basal insulin is associated with better glycaemic control in Type 1 diabetes mellitus 12 months after skills-based structured education in insulin self-management.
Hopkinson HE; Jacques RM; Gardner KJ; Amiel SA; Mansell P
Diabet Med; 2015 Aug; 32(8):1071-6. PubMed ID: 25982032
[TBL] [Abstract][Full Text] [Related]
5. [Neuropathy in too rapid HbA1c decrease].
Sommer C
MMW Fortschr Med; 2015 Jun; 157(11):34. PubMed ID: 26049343
[No Abstract] [Full Text] [Related]
6. Audit of insulin detemir in pregnancy: a retrospective case series.
Shenoy VV; Cook SJ; Parry AF; McIntyre HD
Diabet Med; 2012 Jul; 29(7):958-9. PubMed ID: 22248154
[No Abstract] [Full Text] [Related]
7. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D
Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
[TBL] [Abstract][Full Text] [Related]
8. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
Hemmingsen B; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
[TBL] [Abstract][Full Text] [Related]
9. Assessing the Impact of Insulin Glargine and Detemir Treatment to Serum Total IGF1 Levels in the Insulin-Naive Type 2 Diabetic Patients.
Cander S; Oz Gul O; Dizdar OS; Koca N; Aydın T; Sarandol E; Ersoy C
Metab Syndr Relat Disord; 2017 Jun; 15(5):220-225. PubMed ID: 28394183
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST
Hirsch IB; Franek E; Mersebach H; Bardtrum L; Hermansen K
Diabet Med; 2017 Feb; 34(2):167-173. PubMed ID: 26773446
[TBL] [Abstract][Full Text] [Related]
11. Effect of Insulin Analogs on Frequency of Non-Severe Hypoglycemia in Patients with Type 1 Diabetes Prone to Severe Hypoglycemia: Much Higher Rates Detected by Continuous Glucose Monitoring than by Self-Monitoring of Blood Glucose-The HypoAna Trial.
Agesen RM; Kristensen PL; Beck-Nielsen H; Nørgaard K; Perrild H; Jensen T; Parving HH; Thorsteinsson B; Tarnow L; Pedersen-Bjergaard U
Diabetes Technol Ther; 2018 Mar; 20(3):247-256. PubMed ID: 29565719
[TBL] [Abstract][Full Text] [Related]
12. Glycemic Control in Adult Type 1 Diabetes Patients with Insulin Glargine, Insulin Detemir, or Continuous Subcutaneous Insulin Infusion in Daily Practice.
Rautiainen P; Tirkkonen H; Laatikainen T
Diabetes Technol Ther; 2018 May; 20(5):363-369. PubMed ID: 29741925
[TBL] [Abstract][Full Text] [Related]
13. A 1-year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal-bolus insulin therapy (Kumamoto Insulin Degludec Observational study).
Shimoda S; Sato M; Sekigami T; Motoshima H; Yoshimura R; Fukuda K; Matsuo Y; Noda H; Okubo M; Ichimori S; Fujisawa K; Fukunaga M; Araki E;
J Diabetes Investig; 2016 Sep; 7(5):703-10. PubMed ID: 27181264
[TBL] [Abstract][Full Text] [Related]
14. Severe autonomic neuropathy treated with subcutaneous insulin infusion.
Prendergast JJ; Aubry W
Diabetes Care; 1996 Jan; 19(1):90. PubMed ID: 8720543
[No Abstract] [Full Text] [Related]
15. Higher insulin detemir doses are required for the similar glycemic control: comparison of insulin detemir and glargine in children with type 1 diabetes mellitus.
Abalı S; Turan S; Atay Z; Güran T; Haliloğlu B; Bereket A
Pediatr Diabetes; 2015 Aug; 16(5):361-6. PubMed ID: 25039448
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of insulin detemir versus glargine in patients with diabetes: a systematic review and meta-analysis.
Rezaei S; Taheri A; Taheri S; Kasirzadeh S; Fatemi B; Sorato MM
Expert Rev Clin Pharmacol; 2022 Jun; 15(6):767-777. PubMed ID: 35579011
[TBL] [Abstract][Full Text] [Related]
17. Real-world experience of using basal insulin analogues in children with type 1 diabetes: is twice-daily dosing of insulin detemir justified?
Dayal D; Rohilla L
Pediatr Endocrinol Diabetes Metab; 2019; 25(2):103-105. PubMed ID: 31343144
[No Abstract] [Full Text] [Related]
18. Much ado about nothing? A real-world study of patients with type 2 diabetes switching Basal insulin analogs.
Wei W; Zhou S; Miao R; Pan C; Xie L; Baser O; Gill J
Adv Ther; 2014 May; 31(5):539-60. PubMed ID: 24831915
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Hypoglycemia and Safety Outcomes With Long-Acting Insulins Versus Insulin NPH in Pregestational and Gestational Diabetes.
Sleeman A; Odom J; Schellinger M
Ann Pharmacother; 2020 Jul; 54(7):669-675. PubMed ID: 31893932
[No Abstract] [Full Text] [Related]
20. Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia.
Johansen OE; Vanberg PJ; Kilhovd BK; Jørgensen AP
Vasc Health Risk Manag; 2009; 5(1):121-8. PubMed ID: 19436668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
